Celldex Therapeutics ((CLDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Celldex Therapeutics is conducting a Phase 2 study titled A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The ‘EvolvE’ Study). The study aims to evaluate the efficacy and safety of barzolvolimab in treating adult patients with active eosinophilic esophagitis, a chronic inflammatory condition of the esophagus.
Intervention/Treatment: The study tests barzolvolimab, a biological treatment administered subcutaneously every four weeks. The primary goal is to determine its effectiveness in reducing symptoms of eosinophilic esophagitis compared to a placebo.
Study Design: This interventional study uses a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are all blinded. The primary purpose is treatment-focused.
Study Timeline: The study began on June 1, 2023, and is currently active but not recruiting. The primary completion and estimated completion dates are set for June 26, 2025, which marks when the final data collection for the primary outcome measure is expected.
Market Implications: The update on this study could influence Celldex Therapeutics’ stock performance, as positive results might boost investor confidence and market value. The competitive landscape in the treatment of eosinophilic esophagitis is evolving, and successful outcomes could position Celldex favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.